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Abstract
Background:  Chronological changes of the incidence of congenital cytomegalovirus (CMV)
infection and the longitudinal prognosis in children with asymptomatic congenital infection were
investigated.
Methods: Congenital CMV infection, as demonstrated by isolation of the virus within the first
week of life, was diagnosed in infants born in Sapporo, Japan, during the 26-year period between
1977 and 2002.
Results: Congenital infection was diagnosed in 37 (0.31%) of 11,938 infants. Thirty-two infants
were (86.5%) asymptomatic and 5 (13.5%) were symptomatic at birth.
Conclusions: Although a decrease in the total incidence of congenital CMV infection has been
seen in recent years, screening of congenital infection at birth seems to be necessary to detect late-
onset neurodevelopmental sequelae.
Background
Human cytomegalovirus (CMV) is the most common
cause of congenital and perinatal infections throughout
the world. The prevalence of congenital CMV infection
varies widely between different populations (0.2–3.0%).
[1] Less than 5% of the infants with congenital CMV infec-
tion have typical symptoms of cytomegalic inclusion dis-
ease (CID), another 5% have atypical symptoms of CID,
and the remainder (90%) are asymptomatic at the time of
delivery. Factors that have been associated with a poor
neurodevelopmental prognosis include the presence of
microcephaly, chorioretinitis, intracranial calcification,
hydrocephalus or neurologic abnormalities at birth. [2-4]
A decrease in the prevalence of serum antibodies against
CMV has been documented in recent years in conse-
quence to improvement in the social and economic con-
ditions in Japan especially in the last 20 years. [5-7] We
have studied the incidence of congenital CMV infection in
Japan as reported previously. [8,9]
Although asymptomatic at birth, 5 to 17% of infants with
these asymptomatic congenital CMV infections will
develop progressive sensorineural hearing loss (SNHL) or
other neurodevelopmental difficulties within first 4 years
of life. [10,11] Follow-up studies in children with asymp-
tomatic congenital CMV infection have shown that SNHL
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is the most common consequence of this infection. How-
ever, prediction of which infants will have developmental
disabilities remains controversial. Immunological factors
may be associated with the pathogenesis of neurological
sequelae. It is possible that progression of neurologic
complications is related to the persistent viral infection
and replication of CMV or host immunological response
to infection.
We studied chronological changes of the incidence of con-
genital CMV infection during 26 years in Japan and the
longitudinal prognosis in children with asymptomatic
congenital infection according to growth, cognitive func-
tion and the presence and progression of SNHL.
Methods
Patients
Two hospitals (one is Sapporo Medical University Hospi-
tal and another one is an affiliated hospital) within the
city of Sapporo, Japan were selected for the study. There
were no differences between the infants screened and not
screened. This paper included the infants previously
reported. [8] In a prospective study newborns were
screened for the presence of CMV in urine. Congenital
CMV infection, as demonstrated by isolation of the virus
within the first week of life, was diagnosed with a success-
ful virus isolation test in infants born in the city of Sap-
poro during the 26-year period from January 1977
through December 2002.
The authors evaluated the symptomatic and asympto-
matic infants according to the medical records. Reports of
symptomatic infants were systematically reviewed to con-
firm symptomatic status. Children were determined to
have symptomatic congenital CMV infection if they had
any of the following signs or symptoms during the new-
born period: significant intrauterine growth retardation;
microcephaly; chorioretinitis; petechiae; hepatosplenom-
egaly; intracranial calcification; hydrocephalus; severe
liver dysfunction or direct hyperbilirubinemia. Neonates
with none of these findings were considered to have an
asymptomatic congenital CMV infection. Symptomatic
and asymptomatic CMV-infected infants were followed
up clinically at least for 7 years. Audiologic, neurodevel-
opmental and psychointellectual assessments, serological
study and urine cultures for CMV were performed. Repeat
audiologic tests were completed at certain age intervals to
evaluate hearing function. We used the definition
reported in previous reports to define hearing loss in the
children with congenital CMV infection. [10] We detected
hearing loss stability through repeated testing.
Serological tests
Anti-HCMV IgG and IgM were determined using commer-
cially available enzyme-linked immunosorbent assay
(ELISA) kit (Medac Diagnostika, Hamburg, Germany).
Isolation of CMV from clinical specimens
CMV from urinary specimens was isolated according to
the standard tissue culture technique using MRC-5 cells.
The presence of CMV was confirmed by observation of its
characteristic cytopathic effect (CPE) and by immunoflu-
orescent staining with monoclonal antibodies against
human CMV (HCMV) immediate early (IE) and early (E)
antigens. [12]
Detection of intracellular cytokines-positive CD4+ T cells 
in specific response to CMV antigen
We designed in match control cases in the study. Samples
of whole blood were obtained from 6 children with
asymptomatic congenital CMV infection (1 month, 2
months, 3 months, 1 year and 2 months, 2 years and 4
months, 5 years and 3 months of age; 4 female and 2
male) and from 6 healthy children of 1 to 5-years of age
with serum anti-CMV IgG antibody without serum anti-
CMV IgM antibody and no viral excretion in to urine
(considered as latent condition of postnatal CMV infec-
tions). All 6 children with asymptomatic congenital CMV
infection excrete the virus into urine at the time of exami-
nation. Intracellular cytokines (ICC)-, interferon (IFN)-γ
and tumor necrosis factor (TNF)-α-, positive CD4+ T cells
in specific response to CMV antigen were detected accord-
ing to the methods reported previously. [13-15]
Growth pattern
Head circumference, height and weight at 3 years or older
were assessed using Z scores according to age and gender
for height, weight, weight for height and head
circumference.
Neurodevelopmental and intellectual assessments
Age-appropriate intellectual testing was performed at each
scheduled visit. For the purpose of this study results of
testing done at 6 years of age using the Wechsler Intelli-
gence Scale for Children (WISC-III) were used for evalua-
tion. For purposes of this study, the IQ/developmental
quotient obtained at the latest evaluation was used. Out-
come variables were normal intelligence (IQ/DQ >= 90),
mental retardation (IQ/DQ <70), severe mental retarda-
tion (IQ/DQ <50), and the presence of major motor defi-
cits. A major motor deficit was defined as the presence of
motor abnormalities, such as hypertonia and spasticity
that impaired the ability of the patient to perform tasks of
daily living.
Auditory brainstem response test
The hearing loss was assessed using the standard auditory
brainstem response (ABR) test. Children were tested in a
quiet room or in a soundproof and faradized booth whileBMC Infectious Diseases 2004, 4:22 http://www.biomedcentral.com/1471-2334/4/22
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sleeping. Surface electrodes were attached in Cz (active),
in Fz (ground) and at the ear lobes as reference with a two-
channel montage. The stimuli were rarefaction clicks
delivered monaurally through TDH 39 earphones at a rep-
etition rate of 11.1/s with 10-dB step increases in intensity
until the wave V became indistinguishable from the base-
line. Responses to 2000 clicks were averaged. For each
recording condition trials were conducted at least in
duplicate.
Results
Congenital CMV infection was diagnosed in 37 (0.31%)
of 11,938 infants born between 1977 and 2002. In the
CMV follow-up study 32 (86.5%) were diagnosed as
asymptomatic and 5 (13.5%) as symptomatic congenital
CMV infection (Table 1). There were 20 (54.1%) male
subjects and 17 (45.9%) were female. The duration of
urine secretion between symptomatic and asymptomatic
congenital CMV infection was 24 ± 3.2 and 28 ± 5.6
months respectively. The shortest duration of urinary
excretion of CMV was 6 months, and the longest duration
was 6.5 years. Recurrence of viral excretion after a negative
culture was not documented. A decrease in the total inci-
dence of congenital CMV infection has been seen in these
26 years of the study especially in recent years. However,
the incidences of symptomatic congenital CMV infection
have been slightly increased.
From this basic CMV-infected population identified in the
present study, children with no symptoms at birth but
who developed other neurologic disturbances (i.e., mani-
festing clinical evidence of hypotonia, spasticity, hemi-
paresis, delayed motor development, seizures during the
first years of life) or showed seroconversion of antibodies
against CMV after birth were not identified. Out of 32
asymptomatic CMV-infected infants, 21 were followed up
clinically at least for 7 years. Of the 21 children evaluated
with asymptomatic CMV infection, 18 (85.7%) had an
IQ/DQ of >= 90, 3 (14.3%) had an IQ/DQ of 70 to 89,
and none had a major motor disorder on follow-up. Chil-
dren whose IQ were between 70–89 were categorized as
borderline at later examinations. Although all 21 children
with normal findings on head CT or MRI had a good
prognosis, one had growth retardation. Hearing evalua-
tions were also performed during follow-up of 17 chil-
dren, and 2 had late-onset SNHL (mild bilateral and
moderate unilateral) detected after the first years of life. In
the children with SNHL hearing loss was diagnosed at the
ages of 2 and 3. When children with SNHL detected were
compared with the children with normal hearing, no sig-
nificant differences in cognitive and motor functions were
noted (Table 2).
The frequencies of IFN-γ and TNF-α-positive CD4+ cells
among 6 children with asymptomatic congenital CMV
infection were investigated. The frequencies were 0.024 to
1.833 (0.567 ± 0.244 SD)% for IFN-γ and 0.043 to 1.974
(0.523 ± 0.236 SD)% for TNF-α. The frequencies of IFN-γ
and TNF-α-positive CD4+ cells among 6 healthy children
of 1 to 5-years of age with serum anti-CMV IgG antibody
without serum anti-CMV IgM antibody and no viral excre-
tion in to urine (healthy controls) were 0.000 to 0.200
(0.090 ± 0.051SD)% for IFN-γ and 0.000 to 0.140 (0.048
± 0.025 SD)% for TNF-α. Frequencies of CMV-specific
CD4+ T cells detected by intracellular cytokine staining,
both IFN-γ and TNF-α, were significantly higher in 6 chil-
dren with asymptomatic congenital infection than those
in 6 healthy children of 1 to 5-years of age with serum
Table 1: Incidence of congenital CMV infection by era in Sapporo, Japan
Era No. of neonates screened No. of congenital CMV 
infection (%)
No. of symptomatic congenital CMV 
infection (%)
1977–1981 3,084 14 (0.45%) 1 (0.032%)
1982–1985 2,814 10 (0.36%) 1 (0.036%)
1986–1990 2,097 7 (0.33%) 1 (0.048%)
1991–1996 1,898 3 (0.16%) 1 (0.053%)
1997–2002 2,045 3 (0.15%) 1 (0.049%)
1977–2002 11,938 37 (0.31%) 5 (0.042%)
Table 2: Characteristics of 21 children with asymptomatic 
Congenital CMV infection
Clinical Characteristics No. of Positive / No. of 
Tested
Growth Retardation
Height less than -2 SD 1 / 21
Weight less than -2 SD 1 / 21
Mental Retardation 0 / 21
IQ/DQ
>= 90 18 / 21
70 to 89 3 / 21
Sensorineural Hearing Loss 2 / 17
Unilateral (moderate, 46–70 dB) 1 / 17
Bilateral (mild, 21–45 dB) 1 / 17BMC Infectious Diseases 2004, 4:22 http://www.biomedcentral.com/1471-2334/4/22
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anti-CMV IgG antibody without serum anti-CMV IgM
antibody and no viral excretion in to urine (p < 0.01).
Discussion
Primary infection of CMV during pregnancy was associ-
ated with an increased risk of developmental or intellec-
tual deficit in the offspring. Although CMV can be
transmitted to the fetus even if there is preconceptional
maternal immunity, reinfection or reactivated latent
infection might be an important determinant of develop-
mental and intellectual impairment in the offspring. The
population of seropositive women of childbearing age in
low socioeconomic community is about 85% and about
55% in populations of high socioeconomic status. [1]
In certain countries parental interest groups have called
for screening programs for the general obstetric popula-
tion in an attempt to reduce the rate of fetal damage with
congenital CMV infection. Since annual live births in
Japan used to be approximately 1.22 million, four to five
thousand infants with congenital CMV infection were pre-
sumed to be born each year. Congenital CMV infection is
an unsolved public health problem, unlikely to be solved
by means other than immune prophylaxis.
Prior studies have shown prolonged viral excretion with
congenital CMV infection, and speculated persistent viral
replication was a possible explanation for the develop-
ment of sequelae. Furthermore recent reports have docu-
mented the hearing and vision loss may be progressive or
late onset. Although progressive hearing loss in children
with asymptomatic congenital CMV infection has been
described before, less is known about fluctuating hearing
loss after asymptomatic congenital CMV infection. [16]
Congenital CMV infection can be definitively diagnosed
only in the newborn period, so many of these infections
remain undetected. Of the children with asymptomatic
congenital CMV infection, only a few infants had an audi-
tory screen based on recognition of congenital CMV infec-
tion as the risk factor. All the other neonates with
asymptomatic congenital CMV infection who had audi-
tory screening were tested because of risk criteria other
than CMV infection. Although we did not detect very
severe neurological sequelae in children with asympto-
matic congenital infection compared to the previous
reports, all children with congenital CMV infection
should be screened for hearing loss. [10,11]
The frequencies CMV-specific CD4+T cells were correlated
with the condition of viral infections such as primary
infection or reactivation and positive for other virological
makers, and reflect the change of adoptive immunity
against CMV. [14,15] The ICC staining to detect CMV-spe-
cific CD4+ T cells were also available for the evaluation of
immunological conditions in children with symptomatic
congenital CMV infection. [17] From the results of present
study a high frequency of CMV-specific CD4+ T cells may
indicate the presence of stimulation against cellular
immunity related to asymptomatic congenital CMV infec-
tion. The ICC staining assay can be useful as a tool for real-
time monitoring of CMV-specific cellular immunity in
congenitally infected children. These findings should
assist pediatricians, neonatologists, neurologists, develop-
mentalists, and infectious disease specialists in counseling
families to assess the condition of children with congeni-
tal CMV infection.
Despite the lack of information on possible sequelae in
approximately one third of the children with congenital
CMV infection, our findings indicate 2 of 17 (11.8%)
infants with asymptomatic congenital CMV infection had
late-onset SNHL. Delayed-onset SNHL followed congeni-
tal CMV infection would not have been identified by uni-
versal screening of newborns for hearing. Infants with
symptomatic disorders at birth are more likely to be iden-
tified and have appropriate virological testing for congen-
ital CMV infection in the newborn period. These infants
will likely have a hearing evaluation completed at the time
of diagnosis. However, infants with asymptomatic infec-
tion may not be recognized as being at increased risk for
late-onset neurodevelopmental disorders.
In summary the total incidence of congenital CMV infec-
tion in 11, 938 children in Sapporo, Japan was 0.31%,
between 1977 and 2002. Although a decrease in the total
incidence of congenital CMV infection has been seen in
recent years, the incidences of symptomatic congenital
have been slightly increased. As a decrease in the preva-
lence of serum antibodies against CMV has been docu-
mented in recent years, the incidence of symptomatic
congenital infection may be related to that of primary
CMV infection during pregnancy. Congenital CMV infec-
tion as the probable leading infectious cause of SNHL in
childhood. Each year more children will continue to have
late-onset neurodevelopmental disorders caused by con-
genital CMV infection. Entirely new approaches to pre-
vention and treatment of congenital CMV infection are
necessary, including antiviral interventions and the devel-
opment of a vaccine strategy.
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